Skip to main content
LITTLE GREEN PHARMA LTD logo

LITTLE GREEN PHARMA LTD — Investor Relations & Filings

Ticker · LGP ISIN · AU0000074924 ASX Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2022-11-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX LGP

About LITTLE GREEN PHARMA LTD

https://www.littlegreenpharma.com/

Little Green Pharma Ltd is a vertically integrated medicinal cannabis company focused on the cultivation, production, and distribution of pharmaceutical-grade cannabis medicines. The company operates advanced cultivation and manufacturing facilities, producing a diverse range of products including oils and dried flower. Adhering to Good Manufacturing Practice (GMP) standards, it ensures product consistency and safety across its entire supply chain, from genetics and breeding to final delivery. Little Green Pharma serves both domestic and international markets, maintaining a significant presence in Europe, including Germany and the United Kingdom. The company is committed to advancing clinical research and development to support the therapeutic use of cannabis for various medical conditions, focusing on patient-centric care and high-quality delivery systems.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 30 pages 3.3MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half Year Financial Report' for the period ended 30 September 2022, indicating it is a financial report covering a period shorter than a full fiscal year. It contains detailed financial statements such as the Condensed Consolidated Statement of Financial Position, Profit and Loss, Cash Flows, and Notes to the Financial Statements. It also includes Directors' Report, Auditor's Review Report, and detailed operational and financial commentary. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is not merely an announcement or a certification. The content aligns with the definition of an Interim / Quarterly Report (IR). H1 2023
2022-11-29 English
Ethics approval for CBD Phase III clinical trial 3 pages 261.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 30 November 2022 regarding the receipt of ethics approval for a Phase III clinical trial for a Schedule 3 CBD drug registration in Australia. It discusses the company's plans for a clinical trial and potential product registration but does not contain any financial statements, earnings data, or detailed financial analysis. The document is an announcement of a regulatory milestone and future plans rather than a financial report or detailed investor presentation. It is not a report publication announcement since it does not mention the release or availability of a report. It is also not a management or board change announcement, nor does it relate to capital structure, voting results, or legal proceedings. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about clinical trial ethics approval and product development plans.
2022-11-29 English
LGP wins National Export Award for International Health 2 pages 127.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 25 November 2022, celebrating Little Green Pharma's win at the Australian National Export Awards in the International Health category. It contains no financial data, no regulatory filings, no voting results, no management changes, no earnings information, or any other report type content. It is a company announcement about an award received, which does not fit into any specific financial or regulatory report category. Given the content and length (3,716 characters), it is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2022-11-24 English
LGP significantly expands flower portfolio 2 pages 381.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 24 November 2022 from Little Green Pharma Ltd. It announces the commercial launch of new high-THC cannabis flower products in the Australian market, expanding the company's product portfolio. The content focuses on product and business updates rather than financial results, regulatory filings, or shareholder meeting materials. The document is relatively short (4795 characters) and serves as a business update or capital/financing-related announcement about product expansion and supply chain ownership. It does not contain financial statements, audit information, or detailed management discussion. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to business expansion and product commercialization which impacts the company's capital and market position.
2022-11-23 English
Change in substantial holding 9 pages 361.5KB
Regulatory Filings
2022-11-21 English
Update Four 20 Pharma and French trial extension 2 pages 172.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 21 November 2022 from Little Green Pharma Ltd. It provides an update on the status of an exclusive supply agreement with Four 20 Pharma GmbH, which has ended due to unmet conditions precedent. It also informs about the French Government's extension of a medicinal cannabis trial period. The document is relatively short (3868 characters) and primarily serves as a business update rather than a detailed financial report or regulatory filing. There are no financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content focuses on operational updates and contractual matters, which fits best under general regulatory announcements. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-11-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.